Three market reports on cervical total disc replacement will describe three different industries. One sizes the global market at $451 million in 2025, reaching $775 million by 2032. Another opens at $3.33 billion and forecasts $8.09 billion by 2030. A third bundles cervical with lumbar and lands near $600 million for both. An eightfold spread is not a difference of opinion about growth rates. Somebody’s number is wrong.
Orthofix supplies the test. In 2024 the company booked $23.4 million in global net sales for the M6-C and M6-L together, a family with over 70,000 implants across more than 20 countries. Work backwards from that and a $3.3 billion market would require something north of a hundred M6-scale franchises. There aren’t a hundred. There are maybe eight that matter, and knowing which eight is worth more than any forecast.
The full census
Start with what actually exists, because almost nobody lists it in one place. Approved in the United States for one and two contiguous levels: Prestige LP (Medtronic), Mobi-C (Highridge Medical), Simplify (Globus, via NuVasive), prodisc C Vivo and prodisc C SK (Centinel Spine), and BAGUERA C (Spineart), cleared on 11 August 2026. Approved for a single level: Prestige ST and Bryan (Medtronic), prodisc C and prodisc C Nova (Centinel Spine), Secure-C and PCM (Globus), Synergy Disc (Synergy Spine Solutions), and the M6-C (Orthofix), approved but discontinued since February 2025. In the US pipeline, Dymicron’s Triadyme-C holds an IDE granted in July 2025.
Outside the US the field is wider and older. MOVE-C (NGMedical) is CE marked, TGA approved and selling in 25 countries. activ C (Aesculap), Discover (DePuy Synthes), Rotaio (Signus), Discocerv and CP-ESP (FH Orthopedics) have European histories of varying length and commercial health. Several once-prominent names — Kineflex-C, NuNec, CerviCore, Freedom — never converted trials into durable commercial positions and are effectively gone.
Fourteen of those devices hold FDA approval. Nearly forty exist worldwide, against a US segment that performs a few thousand cases a year. Crowded is not the word. Overpopulated is.
Good evidence, stubborn adoption
The clinical file is strong, which is what makes the commercial picture so odd. Preserving a motion segment instead of eliminating it should lower the load handed to adjacent levels, and the long-term IDE follow-ups have mostly borne that out: higher composite success at two levels, secondary surgery rates around a quarter of ACDF, shorter stays, faster return to work, lower hospital cost per case.
Then look at the volume. The American Spine Registry’s 2026 report logs 153,601 cervical cases from 2015 to 2024. ACDF took 62.2%. Posterior fusion, 24.5%. Disc replacement: 3.2%.
Medicare data points the same way and adds an unpleasant detail. Primary CDA volume flattened after 2018 and is projected at roughly 9,400 cases a year by 2035, while removal arthroplasty is projected to grow near 23% annually. Medicare is admittedly the wrong denominator for a 44-year-old commercially insured patient. Even discounting for that, the explant curve is steeper than the implant curve.
Nothing here is a technology problem. It’s reimbursement that still argues about two-level cases, an implant that costs more than a cage and a plate, indication criteria that rule out most degenerative necks, and surgeons trained on fusion who see no reason to retrain.
Depth beats breadth, until it doesn’t
The defining event of the past eighteen months was a company leaving. Orthofix discontinued the M6-C and M6-L in February 2025, took an eight-figure restructuring charge and closed a California facility, citing portfolio focus. Margin was the honest reason. The M6 also carried an unresolved question: published series had linked polyethylene wear debris to osteolysis and aseptic failure requiring revision. Those findings were contested and never fully settled. What matters commercially is that a company with a globally recognised disc concluded the category didn’t justify the capital.
The companies that stayed did so by going deeper rather than wider. Centinel Spine is the clearest case. Its four cervical devices give it the broadest portfolio of any manufacturer in the world, and the prodisc lineage behind them runs back more than three decades and past a million implantations across cervical and lumbar — the longest continuous clinical record in the category by a wide margin. That matters in a way spec sheets miss: with prodisc C, C Nova, C Vivo and C SK, a surgeon can match device to anatomy and pathology within one system and one instrument philosophy, instead of switching platforms mid-portfolio. It is also converting. The Vivo and SK passed 7,500 US procedures within two years of launch, which in a segment this size is not a rounding error.
Medtronic still holds reference share with Prestige LP plus the legacy Prestige ST and Bryan. Highridge Medical carries Mobi-C, which retains the strongest two-level dataset. Globus sits on three approved devices without ever having treated the segment as strategic.
Spineart joined this month. The Geneva company won FDA approval for BAGUERA C at one and two contiguous levels, on two randomised trials enrolling close to 600 US patients against Mobi-C, with more than 80,000 devices sold internationally and ten-year European data showing motion maintained in 85% of implants. Read the regulatory language carefully: the interim analyses supporting the modular PMA met non-inferiority, not superiority.
The materials argument
The most interesting competitive question in the segment is what the bearing surface should be made of, and two companies have staked their positions on it.
Dymicron received IDE approval in July 2025 for Triadyme-C, built around polycrystalline diamond. The pitch is the removal of wear debris from the equation entirely — not reduced particle burden, not a more biocompatible particle, but a bearing couple hard enough that the debate stops being relevant. It is the most technically ambitious answer anyone has offered to the question the M6 left open, and after the way that story ended, the timing is hard to fault.
NGMedical has taken the polymer route, and has the commercial numbers to argue it works. MOVE-C runs a polycarbonate-urethane gliding surface against a TiNbN-coated titanium endplate, with additively manufactured endplates and no polyethylene anywhere in the construct. It delivers a defined neutral zone with axial damping and progressive resistance, and it implants with roughly the instrument burden of a cervical cage rather than the ceremony of a keeled second-generation device — a detail that moves adoption more than any biomechanics paper. The German company reports 2025 revenue up 43% after 90% in 2024, MOVE-C itself up 60%, past 5,000 implants with follow-up to six years, and TGA approval in Australia added last year. Its US IDE for one and two levels finished enrolment in late 2024 and is heading toward PMA. Those figures come from the company rather than audited filings, but a family-owned manufacturer compounding at that rate in a segment a NASDAQ-listed competitor just exited is the single most interesting data point in this article.
Both arguments run into the same inconvenient fact. BAGUERA C, approved this month, uses a mobile polyethylene core. Regulators are not treating polyethylene as disqualifying, and payers certainly aren’t. The post-polyethylene case is a bet on where surgeons will end up, not a settled question, and it should be sold that way.
Where the money is
The economics of this category suit a focused specialist rather than a large-cap cost structure. Orthofix ran the numbers and walked. Centinel built the deepest portfolio in the field and is converting it. NGMedical is compounding at double digits on the same clinical premise, Dymicron is betting on a bearing surface nobody else can make, and Spineart is entering rather than exiting.
The ceiling is set by payers and surgeon habit, not by engineering. Growth will come from two-level indications where reimbursement cooperates, the ASC channel where a shorter stay converts directly into margin, and Asia-Pacific, where the fusion habit is less entrenched. Beyond that it is a replacement war over the same 3%, decided by anatomic fit, instrument simplicity and wear performance. Not by another release about motion preservation.
The SMG cervical disc directory
Fourteen devices hold FDA approval. Nearly forty exist worldwide. Below is our working directory of cervical disc prostheses tracked by SMG — approved, CE marked, regionally licensed, in trials, and in several cases no longer sold but still implanted in patients who will need surveillance for decades. A handful of legacy US devices are covered in the analysis above rather than in the directory. Some entries are global platforms with tens of thousands of implantations behind them. Others were built for a single market and never left it. The point of putting them in one column is not completeness for its own sake: it is the clearest available picture of how many engineering answers this problem has attracted, and how few of them found a commercial home.
- MOVE-C® (NGMedical)
- Triadyme C Cervical Disc (Dymicron)
- PRODISC C Nova (Centinel Spine)
- PRODISC C Total Disc Replacement (Centinel Spine)
- PRODISC C Vivo (Centinel Spine)
- Activ C
- Almas
- Baguera C
- Biolign Disc
- Biomech Cervical Disc Prosthesis
- C Disc cervical prosthesis
- Crea Spine Cervical disc prosthesis
- d-active
- d-flex Titanium
- d-motion
- Dolphin Cervical Mobile Disc with Silicon Elastomer
- DYNALIS-C®
- ESP Cervical Disc
- Freedom®
- LorX® Cervical Disc Prosthesis
- Mobi C
- NEOphytos
- Neosys Cervical Prosthesis
- PAN Cervical Disc Prosthesis
- PCM Cervical Disc
- Phoenix Cervical Disc
- Prestige LP Cervical Disc
- PROCORAL™
- RHINE Cervical Disc System
- RMDYNX Cervical Mobile Prosthesis
- ROTAIO®
- SECURE C Artificial Disc
- SECURE C3
- SECURE®-CR
- Shark Mobile Prosthesis
- Simplify Cervical Disc
- Smart Mobile Prosthesis with Polyethylene
- Synergy Cervical Disc
- Viking Spine Ceramic
- Viking Spine Titanium
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.